The New Zealand Patent Office has granted a patent to Sabinsa for processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin. NZ Patent No: 568652 'Commercial Process for Making Forskolin and its Derivatives' will be in force until February 2, 2027.
The New Zealand Patent Office has granted a patent to Sabinsa for processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin.
NZ Patent No: 568652 'Commercial Process for Making Forskolin and its Derivatives'ÃÂ will be in force until February 2, 2027.
This most recent patent is #63 in Sabinsa...s worldwide Intellectual Property portfolio. Additionally, Sabinsa has more than 50 pending patent applications worldwide. This patent furthers Sabinsa...s ability to protect their Intellectual Property as they make inroads into Oceania. The company recently received Product Information (PI) numbers for ForsLean 10% and 20% from Australia...s TGA (Therapeutic Goods Administration), a division of the Australian Government Department of Health and Ageing, opening the way for ForsLean to enter the Australian market.
Press release by Sabinsa
The Nutritional Outlook Podcast Episode 33: Keeping up with contract manufacturing
July 26th 2024Nutritional Outlook talks to Lauren Samot, commercial innovation leader, and Blayney McEneaney, sales executive at Vitaquest International, about trends within the contract manufacturing space, and the ways in which contract manufacturers like Vitaquest keep up with the market and differentiate themselves from the competition.